NCT01349335View on ClinicalTrials.gov

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions
AscitesHepatic Cirrhosis
Interventions
DRUG

Tolvaptan

tablet, 15 mg, Qd, for 7 days

DRUG

Tolvaptan

tablet, 30 mg, Qd, 7 days

DRUG

placebo

tablet, 30 mg, Qd, 7days.

Trial Locations (1)

200001

Renji hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY